280 related articles for article (PubMed ID: 32006156)
1. The association of body mass index with long-term clinical outcomes after ticagrelor monotherapy following abbreviated dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a prespecified sub-analysis of the GLOBAL LEADERS Trial.
Ono M; Chichareon P; Tomaniak M; Kawashima H; Takahashi K; Kogame N; Modolo R; Hara H; Gao C; Wang R; Walsh S; Suryapranata H; da Silva PC; Cotton J; Koning R; Akin I; Rensing BJWM; Garg S; Wykrzykowska JJ; Piek JJ; Jüni P; Hamm C; Steg PG; Valgimigli M; Windecker S; Storey RF; Onuma Y; Vranckx P; Serruys PW
Clin Res Cardiol; 2020 Sep; 109(9):1125-1139. PubMed ID: 32006156
[TBL] [Abstract][Full Text] [Related]
2. Impact of renal function on clinical outcomes after PCI in ACS and stable CAD patients treated with ticagrelor: a prespecified analysis of the GLOBAL LEADERS randomized clinical trial.
Tomaniak M; Chichareon P; Klimczak-Tomaniak D; Takahashi K; Kogame N; Modolo R; Wang R; Ono M; Hara H; Gao C; Kawashima H; Rademaker-Havinga T; Garg S; Curzen N; Haude M; Kochman J; Gori T; Montalescot G; Angiolillo DJ; Capodanno D; Storey RF; Hamm C; Vranckx P; Valgimigli M; Windecker S; Onuma Y; Serruys PW; Anderson R
Clin Res Cardiol; 2020 Jul; 109(7):930-943. PubMed ID: 31925529
[TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of 1-Month Dual Antiplatelet Therapy (Ticagrelor + Aspirin) Followed by 23-Month Ticagrelor Monotherapy in Patients Undergoing Staged Percutaneous Coronary Intervention (A Sub-Study from GLOBAL LEADERS).
Kawashima H; Tomaniak M; Ono M; Wang R; Hara H; Gao C; Takahashi K; Sharif F; Thury A; Suryapranata H; Walsh S; Cotton J; Carrie D; Sabate M; Steinwender C; Leibundgut G; Wykrzykowska J; de Winter RJ; Garg S; Hamm C; Steg PG; Jüni P; Vranckx P; Valgimigli M; Windecker S; Onuma Y; Serruys PW
Am J Cardiol; 2021 Jan; 138():1-10. PubMed ID: 33065080
[TBL] [Abstract][Full Text] [Related]
4. Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial.
Serruys PW; Takahashi K; Chichareon P; Kogame N; Tomaniak M; Modolo R; Chang CC; Komiyama H; Soliman O; Wykrzykowska JJ; de Winter RJ; Ferrario M; Dominici M; Buszman P; Bolognese L; Tumscitz C; Benit E; Stoll HP; Hamm C; Steg PG; Onuma Y; Jüni P; Windecker S; Vranckx P; Colombo A; Valgimigli M
Eur Heart J; 2019 Aug; 40(31):2595-2604. PubMed ID: 31397487
[TBL] [Abstract][Full Text] [Related]
5. Association of Sex With Outcomes in Patients Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the GLOBAL LEADERS Randomized Clinical Trial.
Chichareon P; Modolo R; Kerkmeijer L; Tomaniak M; Kogame N; Takahashi K; Chang CC; Komiyama H; Moccetti T; Talwar S; Colombo A; Maillard L; Barlis P; Wykrzykowska J; Piek JJ; Garg S; Hamm C; Steg PG; Jüni P; Valgimigli M; Windecker S; Onuma Y; Mehran R; Serruys PW
JAMA Cardiol; 2020 Jan; 5(1):21-29. PubMed ID: 31693078
[TBL] [Abstract][Full Text] [Related]
6. Impact of chronic obstructive pulmonary disease and dyspnoea on clinical outcomes in ticagrelor treated patients undergoing percutaneous coronary intervention in the randomized GLOBAL LEADERS trial.
Tomaniak M; Chichareon P; Takahashi K; Kogame N; Modolo R; Chang CC; Spitzer E; Neumann FJ; Plante S; Hernández Antolin R; Jambrik Z; Gelev V; Brunel P; Konteva M; Beygui F; Morelle JF; Filipiak KJ; van Geuns RJ; Soliman O; Tijssen J; Rademaker-Havinga T; Storey RF; Hamm C; Steg PG; Windecker S; Onuma Y; Valgimigli M; Serruys PW;
Eur Heart J Cardiovasc Pharmacother; 2020 Jul; 6(4):222-230. PubMed ID: 31876907
[TBL] [Abstract][Full Text] [Related]
7. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial.
Vranckx P; Valgimigli M; Jüni P; Hamm C; Steg PG; Heg D; van Es GA; McFadden EP; Onuma Y; van Meijeren C; Chichareon P; Benit E; Möllmann H; Janssens L; Ferrario M; Moschovitis A; Zurakowski A; Dominici M; Van Geuns RJ; Huber K; Slagboom T; Serruys PW; Windecker S;
Lancet; 2018 Sep; 392(10151):940-949. PubMed ID: 30166073
[TBL] [Abstract][Full Text] [Related]
8. Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes: A Post Hoc Analysis of the Randomized GLOBAL LEADERS Trial.
Tomaniak M; Chichareon P; Onuma Y; Deliargyris EN; Takahashi K; Kogame N; Modolo R; Chang CC; Rademaker-Havinga T; Storey RF; Dangas GD; Bhatt DL; Angiolillo DJ; Hamm C; Valgimigli M; Windecker S; Steg PG; Vranckx P; Serruys PW;
JAMA Cardiol; 2019 Nov; 4(11):1092-1101. PubMed ID: 31557763
[TBL] [Abstract][Full Text] [Related]
9. Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial.
Ge Z; Kan J; Gao X; Raza A; Zhang JJ; Mohydin BS; Gao F; Shao Y; Wang Y; Zeng H; Li F; Khan HS; Mengal N; Cong H; Wang M; Chen L; Wei Y; Chen F; Stone GW; Chen SL;
Lancet; 2024 May; 403(10439):1866-1878. PubMed ID: 38599220
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Multivessel PCI.
Takahashi K; Serruys PW; Chichareon P; Chang CC; Tomaniak M; Modolo R; Kogame N; Magro M; Chowdhary S; Eitel I; Zweiker R; Ong P; Ottesen MM; Tijssen JGP; Wykrzykowska JJ; de Winter RJ; Garg S; Stoll HP; Hamm C; Steg PG; Onuma Y; Valgimigli M; Vranckx P; Carrie D; Windecker S
J Am Coll Cardiol; 2019 Oct; 74(16):2015-2027. PubMed ID: 31623758
[TBL] [Abstract][Full Text] [Related]
11. Ticagrelor monotherapy in patients with concomitant diabetes mellitus and chronic kidney disease: a post hoc analysis of the GLOBAL LEADERS trial.
Gao C; Tomaniak M; Takahashi K; Kawashima H; Wang R; Hara H; Ono M; Montalescot G; Garg S; Haude M; Slagboom T; Vranckx P; Valgimigli M; Windecker S; van Geuns RJ; Hamm C; Steg PG; Onuma Y; Angiolillo DJ; Serruys PW
Cardiovasc Diabetol; 2020 Oct; 19(1):179. PubMed ID: 33066794
[TBL] [Abstract][Full Text] [Related]
12. Clinical relevance of ticagrelor monotherapy following 1-month dual antiplatelet therapy after bifurcation percutaneous coronary intervention: Insight from GLOBAL LEADERS trial.
Kogame N; Chichareon P; De Wilder K; Takahashi K; Modolo R; Chang CC; Tomaniak M; Komiyama H; Chieffo A; Colombo A; Garg S; Louvard Y; Jüni P; G Steg P; Hamm C; Vranckx P; Valgimigli M; Windecker S; Stoll HP; Onuma Y; Janssens L; Serruys PW
Catheter Cardiovasc Interv; 2020 Jul; 96(1):100-111. PubMed ID: 31410968
[TBL] [Abstract][Full Text] [Related]
13. Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial.
Kim BK; Hong SJ; Cho YH; Yun KH; Kim YH; Suh Y; Cho JY; Her AY; Cho S; Jeon DW; Yoo SY; Cho DK; Hong BK; Kwon H; Ahn CM; Shin DH; Nam CM; Kim JS; Ko YG; Choi D; Hong MK; Jang Y;
JAMA; 2020 Jun; 323(23):2407-2416. PubMed ID: 32543684
[TBL] [Abstract][Full Text] [Related]
14. Randomized evaluation of ticagrelor monotherapy after 3-month dual-antiplatelet therapy in patients with acute coronary syndrome treated with new-generation sirolimus-eluting stents: TICO trial rationale and design.
Kim C; Hong SJ; Shin DH; Kim BK; Ahn CM; Kim JS; Ko YG; Choi D; Hong MK; Jang Y
Am Heart J; 2019 Jun; 212():45-52. PubMed ID: 30933857
[TBL] [Abstract][Full Text] [Related]
15. Stopping Aspirin Within 1 Month After Stenting for Ticagrelor Monotherapy in Acute Coronary Syndrome: The T-PASS Randomized Noninferiority Trial.
Hong SJ; Lee SJ; Suh Y; Yun KH; Kang TS; Shin S; Kwon SW; Lee JW; Cho DK; Park JK; Bae JW; Kang WC; Kim S; Lee YJ; Ahn CM; Kim JS; Kim BK; Ko YG; Choi D; Jang Y; Hong MK;
Circulation; 2024 Feb; 149(8):562-573. PubMed ID: 37878786
[TBL] [Abstract][Full Text] [Related]
16. Ticagrelor monotherapy beyond one month after PCI in ACS or stable CAD in elderly patients: a pre-specified analysis of the GLOBAL LEADERS trial.
Tomaniak M; Chichareon P; Modolo R; Takahashi K; Chang CC; Kogame N; Spitzer E; Buszman PE; van Geuns RM; Valkov V; Steinwender C; Geisler T; Prokopczuk J; Sabaté M; Zmudka K; Rademaker-Havinga T; Tijssen JGP; Jüni P; Hamm C; Steg PG; Onuma Y; Vranckx P; Valgimigli M; Windecker S; Baber U; Anderson R; Dominici M; Serruys PW
EuroIntervention; 2020 Apr; 15(18):e1605-e1614. PubMed ID: 31845894
[TBL] [Abstract][Full Text] [Related]
17. Impact of proton pump inhibitors on efficacy of antiplatelet strategies with ticagrelor or aspirin after percutaneous coronary intervention: Insights from the GLOBAL LEADERS trial.
Ono M; Onuma Y; Kawashima H; Hara H; Gao C; Wang R; O'Leary N; Benit E; Janssens L; Ferrario M; Żurakowski A; Dominici M; Huber K; Buszman P; Garg S; Wykrzykowska JJ; Piek JJ; Jüni P; Hamm C; Windecker S; Vranckx P; Deliargyris EN; Bhatt DL; Storey RF; Valgimigli M; Serruys PW;
Catheter Cardiovasc Interv; 2022 Jul; 100(1):72-82. PubMed ID: 35500171
[TBL] [Abstract][Full Text] [Related]
18. DAPT Score and the Impact of Ticagrelor Monotherapy During the Second Year After PCI.
Chichareon P; Modolo R; Kawashima H; Takahashi K; Kogame N; Chang CC; Tomaniak M; Ono M; Walsh S; Suryapranata H; Cotton J; Koning R; Akin I; Kukreja N; Wykrzykowska J; Piek JJ; Garg S; Hamm C; Steg PG; Jüni P; Vranckx P; Valgimigli M; Windecker S; Onuma Y; Serruys PW
JACC Cardiovasc Interv; 2020 Mar; 13(5):634-646. PubMed ID: 32139222
[TBL] [Abstract][Full Text] [Related]
19. Randomized evaluation of 5-month Ticagrelor monotherapy after 1-month dual-antiplatelet therapy in patients with acute coronary syndrome treated with drug-coated balloons: REC-CAGEFREE II trial rationale and design.
Gao C; Zhu B; Liu J; Jiang Z; Hu T; Wang Q; Liu Y; Yuan M; Li F; Zhang R; Xia J; Onuma Y; Wang D; Serruys P; Tao L;
BMC Cardiovasc Disord; 2024 Jan; 24(1):62. PubMed ID: 38245724
[TBL] [Abstract][Full Text] [Related]
20. A randomized clinical trial comparing long-term clopidogrel vs aspirin monotherapy beyond dual antiplatelet therapy after drug-eluting coronary stent implantation: Design and rationale of the Harmonizing Optimal Strategy for Treatment of coronary artery stenosis-Extended Antiplatelet Monotherapy (HOST-EXAM) trial.
Lee H; Koo BK; Park KW; Shin ES; Lim SW; Rha SW; Bae JW; Jeon DW; Oh SK; Hur SH; Kim BS; Lee JH; Park TH; Lee NH; Kim HS;
Am Heart J; 2017 Mar; 185():17-25. PubMed ID: 28267471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
